Please ensure Javascript is enabled for purposes of website accessibility

5 Stocks Making Cash

By Rich Duprey - Updated Apr 5, 2017 at 7:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Top stocks with a proven history of generating lots of free cash flow.

Had Jerry Maguire been an investor instead of a fictional sports agent, he might have become famous for yelling, "Show me the cash flow!"

Earnings come and go, and the green-eyeshade types can legally manipulate it to mask a company's true operations. Yet its ability to generate cash -- what comes in the register and goes out the door -- remains the preeminent indicator of company's worth. In short, cash is king.

Below, we'll look at companies that have proven themselves prodigious generators of free cash flow (FCF) -- the amount of money a company has left over that it could potentially pay to its investors. We'll find companies that have generated compounded free cash flow growth rates exceeding 25% annually over the past five years, then pair them with the opinions of the more than 120,000 members of the Motley Fool CAPS investor intelligence community, to see which ones might have the best chance of outperforming the market.

Over the first 20 months since CAPS began tracking the data, four-star stocks have outperformed the market by more than seven percentage points, while five-star stocks did even better. Keeping an eye on these top stocks might signal your best opportunity to capture those gains.

Company

Levered FCF
5-Yr CAGR, %

CAPS Rating
(5 stars max.)

Celgene (NASDAQ:CELG)

339.4%

****

Dynamic Materials (NASDAQ:BOOM)

32.7%

*****

Eli Lilly (NYSE:LLY)

46.4%

****

Lear (NYSE:LEA)

30.7%

**

Marvell Technology (NASDAQ:MRVL)

45.3%

****

Source: Capital IQ, a division of Standard & Poor's; Motley Fool CAPS. CAGR=Compounded annual growth rate.

Generating copious amounts of cash doesn't make a company an automatic buy. But having looked at Enron's cash flows instead of its earnings would have saved many investors a lot of grief. Warren Buffett understands that the value of a company today is calculated by its discounted future cash flows, so use this list as a jumping-off point to dig deeper into the piles of cash.

Ka-ching!
With a large and extensive pipeline of potential therapies for treating cancer, inflammation diseases, and more, Celgene has also seen its multiple myeloma treatment Revlimid continue to perform as well, increasing sales 72% to $343 million. CAPS member jerrygb777 not only likes the pipeline but thinks that Merck (NYSE:MRK) or some other pharmaceutical with a large bankroll might find the biotech an attractive takeover candidate. "Celgene is the leader in potential cancer drugs. ... With companines like [Pfizer] and [Merck] sitting on large piles of cash there is a takeover possibility but even without that this is a company with a huge future."

Note that while the company generated over $400 million in levered free cash flow over the last year, the large annual growth number above is because five years ago, it generated very little.

Ring the register
That seems similar to the background surrounding Eli Lilly's acquisition of ImClone Systems while awaiting word on passage of its own blood thinner treatment, prasugrel. The acquisition was seen as a risky gamble at the time, but now that the European Union has signed off on the treatment, it needs only FDA approval. Prasugrel will help it compete against Plavix, the blood thinner from Bristol-Myers Squibb (NYSE:BMY) and Sanofi-Aventis, which was a multi-billion dollar drug last year. Erbitux and ImClone's other five pipeline drugs will hopefully justify the $6.5 billion Lilly paid.

A good mix of drugs to treat aging baby boomers will allow Lilly to grow, according to CAPS member mfarland. "Baby boomers are getting older, and they are going to be needing an ever increasing amount of drugs to cure what ails them."

Follow the money
While these stocks have left a trail of dollars, it pays to start your own research on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made all from a stock's CAPS page. Why not head over to the completely free CAPS service and let us hear what you've got to say about these or any other stocks that you think will continue to be rolling in the dough.

On Jan. 12, 2009, Fool co-founder David Gardner, Jeff Fischer, and their Motley Fool Pro team will accept new subscribers to their real-money portfolio service. Motley Fool Pro is investing $1 million of the Fool's own money in long and short positions in a range of securities, including common stocks, put and call options, and exchange-traded funds (ETFs). They also incorporate proprietary CAPS "community intelligence" data into their research. To learn more about Motley Fool Pro and to receive a private invitation to join, simply enter your email address in the box below.

Fool contributor Rich Duprey owns shares of Merck but has no financial position in any of the other stocks mentioned in this article. You can see his  holdings. Dynamic Materials is a Motley Fool Hidden Gems pick. Pfizer and Eli Lilly are Income Investor selections. Pfizer is also an Inside Value pick, and the Fool owns shares. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$301.17 (-0.81%) $-2.45
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$88.93 (-0.29%) $0.26
Marvell Technology Group Ltd. Stock Quote
Marvell Technology Group Ltd.
MRVL
$53.71 (-2.33%) $-1.28
Lear Corporation Stock Quote
Lear Corporation
LEA
$151.26 (2.49%) $3.68
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$74.46 (-0.53%) $0.40
DMC Global Inc. Stock Quote
DMC Global Inc.
BOOM
$22.88 (1.42%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.